BioSpace News Archive

Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, announced the appointment of its new Chief Business Officer.

Outlook Therapeutics, Inc. and AmerisourceBergen announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA).

Akari Therapeutics, Plc today announced financial results for the quarter ended June 30, 2022, as well as pre-clinical and clinical progress on nomacopan and long-acting PAS-nomacopan.

TransCode Therapeutics, Inc. today announced that it will be presenting at the Chardan 6th Annual Genetic Medicines Conference.

Element Biosciences, Inc. announced updated specifications to their AVITI System, increasing the platform’s specifications from 800 million reads per flow cell to 1.0 billion reads per flow cell*, further reducing the price per Gigabase.

Equillium, Inc. today announced interim results from the Type B portion of the EQUALISE study evaluating itolizumab, a first-in-class anti-CD6 monoclonal antibody selectively targeting the CD6-ALCAM pathway, in patients with lupus nephritis (LN).

Dyne Therapeutics, Inc today announced that management is scheduled to participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET.

Opus Genetics today announced the appointment of Adrienne Graves, Ph.D., to its board of directors.

Aktana and Envision Pharma Group announce a strategic partnership that provides medical teams with a comprehensive toolkit for more impactful scientific exchange.

Cresilon, Inc. has entered into a Cooperative Research and Development Agreement (“CRADA”) with Walter Reed Army Institute of Research (“WRAIR”), the largest biomedical research facility administered by the U.S. Department of Defense (“DoD”), to advance the development of medical technologies used for treating traumatic brain injuries, particularly those sustained by soldiers on the battlefield.